Motorsports Games (MSGM) Scheduled to Present at NobleCon18 Investor Conference


Motorsports Games provides a preview of their upcoming presentation at NobleCon18

NobleCon18 – Noble Capital Markets 18th Annual Small and Microcap Investor Conference – April 19-21, 2022 – Hard Rock, Hollywood, FL 100+ Public Company Presentations | Scheduled Breakouts | Panel Presentations | High-Profile Keynotes | Educational Sessions | Receptions & Networking Events

Free Registration Available – More Info


Research News and Advanced Market Data on MSGM


NobleCon18 Presenting Companies

About Motorsport Games

Motorsport Games, a Motorsport Network company, is a leading racing game developer, publisher and esports ecosystem provider of official motorsport racing series throughout the world. Combining innovative and engaging video games with exciting esports competitions and content for racing fans and gamers, Motorsport Games strives to make the joy of racing accessible to everyone. The Company is the officially licensed video game developer and publisher for iconic motorsport racing series across PC, PlayStation, Xbox, Nintendo Switch and mobile, including NASCAR, INDYCAR, 24 Hours of Le Mans, rFactor 2, KartKraft and the British Touring Car Championship (“BTCC”). Motorsport Games is an award-winning esports partner of choice for 24 Hours of Le Mans, Formula E, BTCC, the FIA World Rallycross Championship and the eNASCAR Heat Pro League, among others. Motorsport Games is building a virtual racing ecosystem where each product drives excitement, every esports event is an adventure and every story inspires.

Fresh Vine Wine (VINE) Scheduled to Present at NobleCon18 Investor Conference


Fresh Vine Wine provides a preview of their upcoming presentation at NobleCon18

NobleCon18 – Noble Capital Markets 18th Annual Small and Microcap Investor Conference – April 19-21, 2022 – Hard Rock, Hollywood, FL 100+ Public Company Presentations | Scheduled Breakouts | Panel Presentations | High-Profile Keynotes | Educational Sessions | Receptions & Networking Events

Free Registration Available – More Info


News and Advanced Market Data on VINE


NobleCon18 Presenting Companies

About Fresh Vine Wine

Fresh Vine Wine, Inc. (NYSE American: VINE) is a premier producer of lower carb, lower calorie premium wines in the United States, kicking off a 2022 growth plan following its IPO in mid-December 2021. Fresh Vine Wine’s brand vision is to lead the emerging natural and accessible premium wine category, as health trends continue to accelerate in the US marketplace. The 2020 US wine market was a $69 billion category. Fresh Vine Wine plans to accelerate growth in 2022 by amplifying its marketing, expanding product offerings, and expanding its team. Fresh Vine Wine positions its core brand lineup as an affordable luxury, retailing between $14.99-$22.99. Fresh Vine Wine’s varietals currently include its Cabernet Sauvignon, Chardonnay, Pinot Noir, and Rosé.

Metals & Mining First Quarter 2022 Review and Outlook

Monday, April 4, 2022

Metals & Mining Industry Report

Metals & Mining First Quarter 2022 Review and Outlook

Mark Reichman, Senior Research Analyst, Natural Resources, Noble Capital Markets, Inc.

Refer to end of report for Analyst Certification & Disclosures

  • Mining companies outperform broader market. During the first quarter, mining companies (as measured by the XME) appreciated 36.9% compared to a loss of 4.9% for the S&P 500 index. The VanEck Vectors Gold Miners (GDX) and Junior Gold Miners (GDXJ) ETFs were up 19.7% and 11.8%, respectively. Gold, silver, copper, and zinc futures prices rose 6.5%, 7.5%, 6.7%, and 20.9%, respectively, while lead was down 0.3%. The war in Ukraine has constrained supplies of commodities, everything from fertilizer, grain, oil, natural gas, and metals, and magnified inflationary trends. How long this will continue is uncertain.

  • Outlook for precious metals. The U.S. Dollar Index rose 2.4% during the first quarter, while the yield on a 10-year treasury note rose to 2.33% from 1.51% at year-end 2020. With the U.S. Federal Reserve signaling more aggressive action to combat inflation, further gains for gold may be challenged for the remainder of the year in the face of higher rates and a stronger dollar. However, with consumer and core inflation at 7.9% and 6.4% through February, respectively, real interest rates remain negative and enhance gold’s appeal as a store of value. Moreover, precious metals may be viewed as insurance against expected market volatility and economic uncertainty.

  • Risk of slowing economic growth may impact industrial metals. With the Federal Reserve behind the curve on inflation and an unanticipated war stressing commodity markets, choking back demand and growth may be an obvious choice to combat inflation and supply shortages. A key worry is the risk of recession in the U.S. and abroad versus a softer landing. However, improving supply chains, inventory re-stocking, and greater capital spending could be supportive of pricing, and we believe the long-term investment case for owning industrial metals mining companies remains favorable. However, industrial metals may also be challenged to post further gains into the latter part of the year.

  • Putting it all together. While much uncertainty remains, including the trajectory of the war in Ukraine, the U.S. Federal Reserve will likely achieve its goal of tamping down inflation. Despite a cautious near-term outlook, precious and industrial metals prices could hold up relatively well despite near-term headwinds. As a means of portfolio diversification, exposure to the mining sector is beneficial and investors may want to consider junior mining companies due to more attractive valuations relative to larger cap peers and the potential for increased M&A and industry consolidation.

GENERAL DISCLAIMERS

All statements or opinions contained herein that include the words “we”, “us”, or “our” are solely the responsibility of Noble Capital Markets, Inc.(“Noble”) and do not necessarily reflect statements or opinions expressed by any person or party affiliated with the company mentioned in this report. Any opinions expressed herein are subject to change without notice. All information provided herein is based on public and non-public information believed to be accurate and reliable, but is not necessarily complete and cannot be guaranteed. No judgment is hereby expressed or should be implied as to the suitability of any security described herein for any specific investor or any specific investment portfolio. The decision to undertake any investment regarding the security mentioned herein should be made by each reader of this publication based on its own appraisal of the implications and risks of such decision.

This publication is intended for information purposes only and shall not constitute an offer to buy/sell or the solicitation of an offer to buy/sell any security mentioned in this report, nor shall there be any sale of the security herein in any state or domicile in which said offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or domicile. This publication and all information, comments, statements or opinions contained or expressed herein are applicable only as of the date of this publication and subject to change without prior notice. Past performance is not indicative of future results. Noble accepts no liability for loss arising from the use of the material in this report, except that this exclusion of liability does not apply to the extent that such liability arises under specific statutes or regulations applicable to Noble. This report is not to be relied upon as a substitute for the exercising of independent judgement. Noble may have published, and may in the future publish, other research reports that are inconsistent with, and reach different conclusions from, the information provided in this report. Noble is under no obligation to bring to the attention of any recipient of this report, any past or future reports. Investors should only consider this report as single factor in making an investment decision.


IMPORTANT DISCLOSURES

This publication is confidential for the information of the addressee only and may not be reproduced in whole or in part, copies circulated, or discussed to another party, without the written consent of Noble Capital Markets, Inc. (“Noble”). Noble seeks to update its research as appropriate, but may be unable to do so based upon various regulatory constraints. Research reports are not published at regular intervals; publication times and dates are based upon the analyst’s judgement. Noble professionals including traders, salespeople and investment bankers may provide written or oral market commentary, or discuss trading strategies to Noble clients and the Noble proprietary trading desk that reflect opinions that are contrary to the opinions expressed in this research report.
The majority of companies that Noble follows are emerging growth companies. Securities in these companies involve a higher degree of risk and more volatility than the securities of more established companies. The securities discussed in Noble research reports may not be suitable for some investors and as such, investors must take extra care and make their own determination of the appropriateness of an investment based upon risk tolerance, investment objectives and financial status.

Company Specific Disclosures

The following disclosures relate to relationships between Noble and the company (the “Company”) covered by the Noble Research Division and referred to in this research report.
Noble is not a market maker in any of the companies mentioned in this report. Noble intends to seek compensation for investment banking services and non-investment banking services (securities and non-securities related) with any or all of the companies mentioned in this report within the next 3 months

ANALYST CREDENTIALS, PROFESSIONAL DESIGNATIONS, AND EXPERIENCE

Senior Equity Analyst focusing on Basic Materials & Mining. 20 years of experience in equity research. BA in Business Administration from Westminster College. MBA with a Finance concentration from the University of Missouri. MA in International Affairs from Washington University in St. Louis.
Named WSJ ‘Best on the Street’ Analyst and Forbes/StarMine’s “Best Brokerage Analyst.”
FINRA licenses 7, 24, 63, 87

WARNING

This report is intended to provide general securities advice, and does not purport to make any recommendation that any securities transaction is appropriate for any recipient particular investment objectives, financial situation or particular needs. Prior to making any investment decision, recipients should assess, or seek advice from their advisors, on whether any relevant part of this report is appropriate to their individual circumstances. If a recipient was referred to Noble Capital Markets, Inc. by an investment advisor, that advisor may receive a benefit in respect of
transactions effected on the recipients behalf, details of which will be available on request in regard to a transaction that involves a personalized securities recommendation. Additional risks associated with the security mentioned in this report that might impede achievement of the target can be found in its initial report issued by Noble Capital Markets, Inc. This report may not be reproduced, distributed or published for any purpose unless authorized by Noble Capital Markets, Inc.

RESEARCH ANALYST CERTIFICATION

Independence Of View
All views expressed in this report accurately reflect my personal views about the subject securities or issuers.

Receipt of Compensation
No part of my compensation was, is, or will be directly or indirectly related to any specific recommendations or views expressed in the public appearance and/or research report.

Ownership and Material Conflicts of Interest
Neither I nor anybody in my household has a financial interest in the securities of the subject company or any other company mentioned in this report.

NOBLE RATINGS DEFINITIONS
% OF SECURITIES COVERED
% IB CLIENTS
Outperform: potential return is >15% above the current price
94%
28%
Market Perform: potential return is -15% to 15% of the current price
6%
3%
Underperform: potential return is >15% below the current price
1%
0%

NOTE: On August 20, 2018, Noble Capital Markets, Inc. changed the terminology of its ratings (as shown above) from “Buy” to “Outperform”, from “Hold” to “Market Perform” and from “Sell” to “Underperform.” The percentage relationships, as compared to current price (definitions), have remained the same. Additional information is available upon request. Any recipient of this report that wishes further information regarding the subject company or the disclosure information mentioned herein, should contact Noble Capital Markets, Inc. by mail or phone.

Noble Capital Markets, Inc.
150 East Palmetto Park Rd, Suite 110
Boca Raton, FL 33432
561-994-1191

Noble Capital Markets, Inc. is a FINRA (Financial Industry Regulatory Authority) registered broker/dealer.
Noble Capital Markets, Inc. is an MSRB (Municipal Securities Rulemaking Board) registered broker/dealer.
Member – SIPC (Securities Investor Protection Corporation)

Report ID: 24663
Metals & Mining | April 4, 2022

Eagle Bulk Shipping (EGLE) Scheduled to Present at NobleCon18 Investor Conference


Eagle Bulk Shipping provides a preview of their upcoming presentation at NobleCon18

NobleCon18 – Noble Capital Markets 18th Annual Small and Microcap Investor Conference – April 19-21, 2022 – Hard Rock, Hollywood, FL 100+ Public Company Presentations | Scheduled Breakouts | Panel Presentations | High-Profile Keynotes | Educational Sessions | Receptions & Networking Events

Free Registration Available – More Info


Research News and Advanced Market Data on EGLE


NobleCon18 Presenting Companies

About Eagle Bulk Shipping

Eagle Bulk Shipping Inc. (“Eagle” or the “Company”) is a U.S.-based, fully integrated, shipowner-operator providing global transportation solutions to a diverse group of customers including miners, producers, traders, and end users. Headquartered in Stamford, Connecticut, with offices in Singapore and Copenhagen, Eagle focuses exclusively on the versatile mid-size drybulk vessel segment and owns one of the largest fleets of Supramax/Ultramax vessels in the world. The Company performs all management services in-house (including: strategic, commercial, operational, technical, and administrative) and employs an active management approach to fleet trading with the objective of optimizing revenue performance and maximizing earnings on a risk-managed basis. For further information, please visit our website: www.eagleships.com.

Baudax Bio (BXRX) – Chairman Announces Resignation

Monday, April 04, 2022

Baudax Bio (BXRX)
Chairman Announces Resignation

Baudax Bio is a biopharmaceutical company focused on developing therapies for post-operative pain, peri-operative pain, and anesthesia. The company currently has one approved therapy in ANJESO for post-operative pain. Proprietary ANJESO (meloxicam) injection is the first and only once-daily IV analgesic. The company also has a pipeline of early-stage candidates with two novel neuromuscular blocking agents (NMBAs), a proprietary related reversal agent to their NMBAs, and Dex-IN, an intranasal formulation of dexmedetomidine (Dex) that has sedative, analgesic, and anti-anxiety properties.

Gregory Aurand, Senior Research Analyst, Healthcare Services & Medical Devices, Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

    Resignation announced.  Chairman of the Board of Directors Alfred Altomari announced March 30, 2022, that he was intending to resign. Mr. Altomari has been a director at Baudax Bio since 2019, and was a prior member of the Recro Pharma Board (Recro spun out Baudax Bio to shareholders in 2019). Mr. Altomari has extensive pharmaceutical experience and is currently Chairman and CEO at Agile Therapeutics, and serves on the board of Insmed, Inc.

    Resignation effective with shareholder meeting.  Mr. Altomari announced that his resignation would be immediately following the Annual Meeting of Shareholders to be held May 4, 2022 …


This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision. 

 

Ocugen (OCGN) – Gene Therapy Trial Reaches Progress Milestone

Monday, April 04, 2022

Ocugen (OCGN)
Gene Therapy Trial Reaches Progress Milestone

Ocugen Inc is a clinical stage biopharmaceutical company. It is focused on discovering, developing and commercializing a pipeline of innovative therapies that address rare and underserved eye diseases. Ocugen offers a diversified ophthalmology portfolio that includes novel gene therapies, biologics, and small molecules and targets a broad range of high-need retinal and ocular surface diseases.

Robert LeBoyer, Vice President, Research Analyst, Life Sciences, Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

    Ocugen Meets A Pipeline Milestone Ocugen announced treatment of the first patient in its Phase 1/2 trial for OCU400, the first product from its gene therapy platform to reach clinical trials.  OCU400 delivers genes to correct the genetic mutations that lead to retinitis pigmentosa, an ophthalmic condition that leads to vision loss and blindness. Patient screening began in 1Q22, meeting our expected timeframe for the trial. We see this milestone as good news for the product and the development pipeline.

    Phase 1/2 Trial Is Designed To Show Safety and Efficacy.  The OCU400 Phase 1/2 trial is designed with three cohorts at increasing dose levels. After establishing basic safety at the low dose, two additional cohorts will receive higher doses. The treatment delivers functional copies of the NR2E3 and RHO genes, regulatory genes that affect expression of other genes in the disease pathway. Preliminary …


This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision. 

 

Onconova Therapeutics (ONTX) – Narazaciclib Data Presented At Scientific Industry Conference

Monday, April 04, 2022

Onconova Therapeutics (ONTX)
Narazaciclib Data Presented At Scientific Industry Conference

Onconova Therapeutics Inc is a clinical-stage biopharmaceutical company operating in the US. It focuses on discovering and developing novel small molecule product candidates primarily to treat cancer. The company has created a library of targeted agents designed to work against cellular pathways important to cancer cells. Its product candidates are Single-agent IV rigosertib, Oral rigosertib + azacitidine, IV Briciclib, Recilisib, and ON 123300. The key product candidate Rigosertib is a small molecule which blocks cellular signaling by targeting RAS effector pathways.

Robert LeBoyer, Vice President, Research Analyst, Life Sciences, Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

    Onconova Presented Data At The Next Generation Kinase Inhibitors Summit.  Onconova presented data from narazaciclib studies at an industry meeting attended by academic and corporate scientists. New data is not presented at this type of meeting, but speakers are able to present more information in greater detail than a medical meeting would typically allow. The communication with other scientists in the field also helps to establish a company’s expertise, and can lead to future collaborations, clinical site participation, and corporate partnerships.

    Data Gave An Overview and Summary of Narazaciclib.  Data was presented by Onconova’s Director of Corporate Development, and a session was chaired by Onconova’s CEO. These presentations gave data on narazaciclib’s activity against CDK4, CDK6, and other intermediaries in a pathway that leads to cancer cell growth, proliferation, and metastasis. The data showed potent inhibition consistent with the …


This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision. 

 

Pangaea Logistics (PANL) Scheduled to Present at NobleCon18 Investor Conference


Pangaea Logistics CFO Gianni Del Signore provides a preview of their upcoming presentation at NobleCon18

NobleCon18 – Noble Capital Markets 18th Annual Small and Microcap Investor Conference – April 19-21, 2022 – Hard Rock, Hollywood, FL 100+ Public Company Presentations | Scheduled Breakouts | Panel Presentations | High-Profile Keynotes | Educational Sessions | Receptions & Networking Events

Free Registration Available – More Info


Research News and Advanced Market Data on PANL


NobleCon18 Presenting Companies

About Pangaea Logistics

Pangaea Logistics Solutions Ltd. (NASDAQ: PANL) provides logistics services to a broad base of industrial customers who require the transportation of a wide variety of dry bulk cargoes, including grains, pig iron, hot briquetted iron, bauxite, alumina, cement clinker, dolomite, and limestone. The Company addresses the transportation needs of its customers with a comprehensive set of services and activities, including cargo loading, cargo discharge, vessel chartering, and voyage planning. Learn more at www.pangaeals.com.

Filament Health (FLHLF) – FY2021 Reported With A Review Of Clinical Pipeline Progress

Monday, April 04, 2022

Filament Health (FLHLF)
FY2021 Reported With A Review Of Clinical Pipeline Progress

Filament Health Corp is a natural psychedelic drug discovery and extraction technology company. Its mission is to see safe, approved, natural psychedelics in the hands of everyone who needs them as soon as possible. Filament engages in natural extraction technology commercialization, utilizing its intellectual property portfolio, in-house GMP facility, and Health Canada psilocybin Dealer’s License.

Robert LeBoyer, Vice President, Research Analyst, Life Sciences, Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

    Filament Made Substantial Progress During 4Q21.  Filament Health reported a full year loss of $9.3 million or $(0.06) per share. During the quarter, Filament advanced its clinical pipeline, made licensing agreements, and strengthened its intellectual property. The cash balance at December 31, 2021 was $4.6 million.

    Clinical Trials Have Begun.  During 4Q, Filament announced regulatory clearance for its first clinical trial. This trial began patient treatment in March 2022, testing its naturally-derived psilocybin and its bioactive form, psilocin. The trial has three arms to compare the standard doses of oral psilocybin (PEX010), oral psilocin (PEX020), and sublingual psilocin (PEX030) …


This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision. 

 

GABY Inc. (GABLF) – GABY Inc. Focused on California Cannabis Consolidation

Monday, April 04, 2022

GABY Inc. (GABLF)
GABY Inc.: Focused on California Cannabis Consolidation

Gaby Inc is a wellness company that is engaged in the marketing of a variety of cannabis products, including flowers, concentrates, pre-rolls, edibles, topicals, tinctures, and other products. Some of its brands are Mankind, Sonoma Pacific, 2Rise, Lulu’s, and the Kind Republic. The company operates in two segments, namely licensed and unlicensed channels, both of which are in the manufacturing, distribution, and marketing of wellness products to address a variety of dietary and health concerns. All of its revenue comes from the United States.

Joe Gomes, Senior Research Analyst, Noble Capital Markets, Inc.

Joshua Zoepfel, Research Associate, Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

    Initiating Coverage. We are initiating research coverage on GABY Inc. GABY Inc. is a California-focused cannabis retail consolidator and the owner of San Diego-based Mankind Dispensary, one of the oldest and largest licensed dispensaries in the state. With significant organic and inorganic growth opportunities, we believe GABLF shares present an attractive risk/reward situation.

    Focus on California Consolidation.  GABY’s overarching strategy is to consolidate dispensaries in California. The Company’s first step was the April 2021 acquisition of Mankind Dispensary. The California market remains highly fragmented. No brand owns more than 2.5% of the retail dispensary locations and 4% of overall market share. Ripe for consolidation, in our view …


This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision. 

 

House Overwhelmingly Passes Changes to Retirement Savings



Image Credit: Marco Verch (Flickr)


Retirees May Soon Have More Options as House Passes “Securing a Strong Retirement Act”

 

Raising the required minimum distribution age to 75 (from 72) on retirement accounts will have more impact than many may realize. The House advanced legislation on Tuesday (March 29) raising the age where retirees must take RMDs or face severe IRS penalties. The measure seems to take into account much that is facing retirees, but there are some pitfalls older Americans must be watch as well.

Background

The House of Representatives passed the Securing a Strong Retirement Act, often referred to as the Secure Act 2.0, by a vote of 414-5. The most consequential provisions are below:

  • Raise the age savers must take minimum distributions, or RMDs, from their retirement savings accounts to 73 from 72, effective next Jan. 1, to 74 starting in 2030 and to 75 starting in 2033. *The RMD age was raised to 72 from 70½ by the Secure Act of 2019.
  • Increase the limits on “catch-up contributions for employees ages 62 to 64. In 2021, this age worker was permitted to contribute up to $6,500 to their retirement savings plans beyond the standard limits. The bill would increase the limit to $10,000, beginning in 2024, and indexes it to inflation.
  • Expanded automatic enrollment of workers in employer-sponsored retirement saving plans. Beginning in 2024, employees would be automatically enrolled in plans such as 401(k)s and 403(b)s unless they opt out. Workers’ initial automatic contributions would be between 3% and 10% of pretax earnings, and that amount would be increased by 1% each year until reaching 10%.

    All current 401(k) and 403(b) plans are “grandfathered,” the employer-based plan doesn’t have to comply with this provision. There’s also an exception for businesses with 10 or fewer employees, businesses that have existed for less than three years, church plans, and governmental plans.

  • Reduces the penalty for failure to take RMDs to 25% from 50%. In addition, if this failure is corrected in a timely manner, as defined by the bill, the penalty would be further reduced to 10%.
  • Allows employers to match a worker’s student loan payment by making the same size contribution to that worker’s retirement savings plan. This provision, which will take effect Jan. 1, is to help workers who find it difficult to save for retirement because of student-loan payments. Npt contributing causes them to miss out on their employers’ matching contributions to company-sponsored retirement savings plans.
  • Enhances the Saver’s Credit, which intends to incentivize low- and middle-income Americans to save for retirement with a tax credit of up to $1,000 each year. Today these workers can qualify for a tax credit of 50%, 20%, or 10% of their contributions to a qualified retirement plan, up to $2,000, based on  income level.
  • Creates an online, searchable “retirement savings lost-and-found database” at the Labor Department to help workers and retirees find their lost retirement accounts, including those from previous employers.

People are living longer than ever before, and everyone’s situation is different. Raising the minimum age for a person to take distributions allows more freedom to design around one’s own retirement and tax circumstances.

The purpose of the requiring distributions is that the IRS did not collect taxes on the qualified retirement money when it was earned. RMDs are their way to finally collect. Should savers opt to wait longer, it is likely the IRS will benefit as the savings is likely to grow and the expected time remaining until death is likely to shrink. Therefore, the RMDs will be much larger and taxes would be higher. This could benefit the tax rolls but still benefits the retiree.

Paul Hoffman

Managing Editor, Channelchek

 

Suggested Reading



IRA Investments and Small Cap Stocks



Index Funds Still May Fall Apart over Time





Trading Accounts for Children



Robinhood Continues to Push to Expand Their Users’ Possibilities

 

Sources

https://www.congress.gov/bill/117th-congress/house-bill/2954

https://www.barrons.com/advisor/articles/senators-retirement-security-bill-secure-act-cardin-portman-51638537894

https://www.reportdoor.com/how-the-secure-act-could-trigger-higher-taxes-for-some-retirees/

https://www.barrons.com/articles/secure-act-2-0-retirement-rmd-requirements-51648594141

 

Stay up to date. Follow us:

 

Garibaldi Resources (GGIFF)(GGI:CA) – Geophysical Survey Results Underscore Nickel Mountains Growing Resource Potential

Friday, April 01, 2022

Garibaldi Resources (GGIFF)(GGI:CA)
Geophysical Survey Results Underscore Nickel Mountain’s Growing Resource Potential

Garibaldi Resources Corp is a Canadian-based junior exploration company. It is engaged in the acquisition, exploration, and evaluation of mineral properties located in Canada and Mexico. The company’s projects in Mexico include the La Patilla, the Rodadero, the Tonichi and the Iris project. Its projects in Canada include the PSP and King projects, The Cariboo Copper and Gold project, the Red Lion project, the Grizzly project, the Tora Tora project and the Black Gold project.

Mark Reichman, Senior Research Analyst of Natural Resources, Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

    Significant geophysical survey results. Garibaldi released results from a 2021 Z-Axis Tipper Electromagnetic (ZTEM) survey completed over the company’s 180-square kilometer Nickel Mountain – Palm Springs Project claim groups. Recall that E&L Nickel Mountain represents the first magmatic nickel-copper-cobalt-PGE-rich massive sulphide system identified in the Eskay Camp. The survey identified a large anomalous zone directly below and along trend with mineralized E&L Nickel Mountain gabbro previously confirmed by drilling. The anomaly exceeds 3 kilometers in width and plunges 2 kilometers directly below the nickel-copper-cobalt PGE bearing intrusion which hosts high grade massive sulphides. The finding potentially extends the mineralized zone which could have positive implications for resource size and project economics.

    Growing property-wide exploration potential.  The presence of ZTEM-identified geophysical anomalies coincident with surface mineralization and conductive targets from Versatile Time Domain Electromagnetic (VTEM) surveys provide property-wide targets for magmatic and hydrothermal base and precious metal mineralization with high discovery potential …


This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision. 

 

Blackboxstocks Inc. (BLBX) – A Year to Build Off Of

Friday, April 01, 2022

Blackboxstocks Inc. (BLBX)
A Year to Build Off Of

Blackboxstocks, Inc. is a financial technology and social media hybrid platform offering real-time proprietary analytics and news for stock and options traders of all levels. Our web-based software employs “predictive technology” enhanced by artificial intelligence to find volatility and unusual market activity that may result in the rapid change in the price of a stock or option. Blackbox continuously scans the NASDAQ, New York Stock Exchange, CBOE, and all other options markets, analyzing over 10,000 stocks and up to 1,500,000 options contracts multiple times per second. We provide our users with a fully interactive social media platform that is integrated into our dashboard, enabling our users to exchange information and ideas quickly and efficiently through a common network. We recently introduced a live audio/screenshare feature that allows our members to broadcast on their own channels to share trade strategies and market insight within the Blackbox community. Blackbox is a SaaS company with a growing base of users that spans 42 countries; current subscription fees are $99.97 per month or $959.00 annually. For more information, go to: www.blackboxstocks.com

Joe Gomes, Senior Research Analyst, Noble Capital Markets, Inc.

Joshua Zoepfel, Research Associate, Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

    4Q Results. Blackboxstocks’ management announced their fourth quarter and full year results yesterday, with fourth quarter revenue coming in at $1.69 million, a record for total revenue for the company, and a 62% increase over fourth quarter 2020. We had forecasted $1.53 million. Net loss for the quarter totaled $1.88 million, compared to the fourth quarter 2020’s loss of $518,857, while gross margin was 65.8% compared to 52.0% last year. We estimated net loss to be $610,800 and gross margin of 68.0%.

    Fiscal Year Results.  For the fiscal year, the Company totaled revenue of $6.11 million, a 81.5% increase over fiscal year 2020’s $3.37 million. Gross margin increased year-over-year by 540 basis points to 69.7% from 64.3% in the 2020 fiscal year. The increases in both revenue and gross margin was noted by management as leveraging its strong membership growth, although they did not disclose …


This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision.